Cemiplimab in patients with metastatic or locally advanced cutaneous squamous‑cell carcinoma

05/2020

MUDr. Jindřich Kopecký, Ph.D.

Klinika onkologie a radioterapie LF UK a FN Hradec Králové

SUMMARY

Cutaneous squamous cell carcinoma (cSCC) is one of the most common skin tumors. Surgical intervention remains crucial in the treatment of cSCC. Inoperable or metastatic cSCC is one of the less common but it belongs to incurable diseases. Both systemic preparations (most often cisplatin, 5-fluorouracil) and tyrosine kinase inhibitors are used in systemic treatment. Although a relatively good therapeutic response is achieved with these drugs, their long-term efficacy remains problematic. Cemiplimab is another immunomodulatory drug that targets the PD-1 receptor. The results so far not only have a good therapeutic response, but above all, they maintain their long-term effectiveness. Due to these properties, they have become the drug of choice for inoperable/metastatic cSCC diseases.

Keywords

PD-1 receptor, immunotherapy, cemiplimab, cutaneous squamous cell carcinoma